Source: World Wide Web
Since Genentech, Sanogan Pharmaceuticals, and Spark Therapy, on May 22, Swiss pharmaceutical giant Roche announced the acquisition of sequencing technology company Stratos Genomics, for Roche, this acquisition means that this giant is also striving for a leading position in the field of clinical diagnostics.
In August 2014, Sanogan Pharmaceuticals was acquired by Roche Genentech for US$1.725 billion, and due to Sanogan's deep technical accumulation in the field of estrogen receptor degraders, the acquisition was selected by Roche as another breast cancer drug candidate in addition to the ace drug trastuzumab. It is worth mentioning that Sanogan Pharmaceuticals' last product, ARN-509, was sold to Johnson & Johnson in 2013 for $1 billion, the new prostate cancer drug Ansenke, which was launched last year, which shows its strong strength in cancer treatment.
Following Sanogan, in September, Roche acquired InterMune non-stop to expand its market share in respiratory drugs, and its new drug for fibrotic lung disease, pirfenidone, has been listed in Europe, Japan, China and other places.
In addition to the 2014 merger and acquisition "first year", Roche's hegemony has begun to emerge from the acquisition of the US biotechnology giant Genentech in 2009, and the combination of the two is known as one of the most perfect mergers and acquisitions in the pharmaceutical industry, so Roche has won more than 20 blockbuster drugs in one fell swoop, laying the groundwork for the subsequent creation of bevacizumab, rituximab, and trastuzumab.
Just in the past 2019, the international pharmaceutical industry has experienced a major "reshuffle" - integration, mergers and acquisitions, restructuring, and the collision of new and old fields has brought more sparks. On January 30, Roche announced its 2019 financial report, with a total revenue of $65.12 billion, surpassing the "cosmic big pharmaceutical company" Pfizer's $51.75 billion, becoming the well-deserved first in the pharmaceutical industry.
Of course, from the perspective of revenue growth and merger and acquisition strategies in recent years, Roche has made a significant resource tilt adjustment. Although its three major drugs are still sold out of volume, with the patent protection approaching the "cliff", it has now shown a negative growth trend. Roche is developing vertically in the field of cancer, as well as expanding its territory in the fields of immune diseases, neurological diseases, and eye diseases.
This trend can be seen from the recent acquisition of gene therapy unicorn Spark Therapeutics (Spark Therapeutics), Roche has expanded the combination on the basis of the previous hemophilia and eye disease drug pipeline, which has lasted for its long-term competitiveness in the pharmaceutical field and dispelled some investors' concerns about its "lack of staying power".
All in all, from Genentech to Sanogan to Spark, Roche's ability to grow into today's pharmaceutical hegemon and steadily continue its value is inseparable from a series of major M&A strategies described above. In addition, Roche is also one of the few pharmaceutical companies that can go hand in hand with diagnostic research and development, and it is not difficult to see from its mergers and acquisitions of FMI, Flatiron and other companies that Roche is accelerating the layout of the closed loop from clinical diagnosis to personalized drugs, and this strategic strength of internalizing the M&A industry into its own synergy is also the key to its monopoly position.